Glycoproteins are involved in diverse biological processes ranging from extracellular contact and recognition to intracellular signaling. Crystal structures of glycoproteins would yield tremendous insight into these processes. But glycoprotein structural analysis has been hindered by difficulties in expressing milligram quantities of stable, homogeneous protein and determining which modifications will yield samples amenable to crystallization. We describe a platform, which we have proven to be effective for rapidly screening expression and crystallization of a challenging glycoprotein target. In this protocol, multiple glycoprotein ectodomain constructs are produced in parallel by transient expression of adherent human embryonic kidney (HEK) 293T cells and are subsequently screened for crystals in microscale quantities by free interface diffusion. As a result, recombinant proteins are produced and processed in a native, mammalian environment, and crystallization screening can be accomplished with as little as 65 lg of protein. Moreover, large numbers of constructs can be generated, screened and scaled up for expression and crystallization, with results obtained in 4 weeks.
INTRODUCTION
Glycoproteins are thought to make up about 50% of all human and human pathogen proteins, but relatively few of these structures have been solved to date. Structural biology of glycoproteins is hindered by challenges in achieving high-level expression of soluble, stable and homogenous protein capable of forming well-diffracting crystals. Although attachment and processing of glycans is often a prerequisite for correct protein folding and stability, the chemical and conformational heterogeneity of complex-type glycans displayed on proteins produced in mammalian cells generally inhibits the formation of a well-ordered crystal lattice 1 . Iterative rounds of construct redesign or site-directed mutagenesis of N-or O-linked glycosylation sequons coupled with enzymatic deglycosylation are usually necessary to identify a protein construct suitable for crystallization. Chinese hamster ovary cells 2 , yeast 3 and insect cell-based systems [4] [5] [6] [7] are often used for glycoprotein expression. However, these systems are not ideal for rapid construct screening as initial setup of each stable cell line can be time consuming. Moreover, processing of glycans in yeast, insect and fruit fly cell lines differs from that which occurs in human glycan biosynthetic pathways, possibly influencing protein folding, stability, activity, secretion and immunogenicity [8] [9] [10] [11] . Recent developments using transient transfection protocols of adherent HEK 293T cells have shown greater promise for higher throughput and overall yields of mammalian-expressed glycoproteins [12] [13] [14] . Many structural genomics centers that focus on human proteins now use the HEK293 cell line for expression screening and production 13 , and this cell type is approved by the US Food and Drug Administration for clinical and commercial production of macromolecular therapeutics.
We describe a procedure for screening crystallization using transient expression in adherent HEK293T cells, one-step affinity purification and microfluidic free interface diffusion. This platform allows cloning, expression and crystallization to be performed in approximately 4 weeks, considerably faster than with other current protocols ( Fig. 1) . This protocol is now in standard use for all mammalian-expressed glycoproteins in our laboratory 15 and by several other groups 12, 16 . Its utility is proven by our ability to screen 130 different constructs of the Zaire ebolavirus glycoprotein in complex with seven different antibodies for successful structural determination 15 .
Considerations for test-scale expression system
The main considerations in the selection of a vector for expression of mammalian glycoproteins are:
(i) the plasmid should have a high copy number in Escherichia coli to produce milligram quantities of DNA required for large-scale transient transfections; (ii) the promoter should be strong in mammalian cells; (iii) the plasmid should encode an optimized secretion signal to ensure proper targeting and co-and post-translational processing of the cloned fusion protein; and (iv) the plasmid should encode a high-affinity purification tag to bind low yields of the resulting secreted protein from large volumes of conditioned media, and also serve as a highaffinity epitope tag for protein detection.
Although many commercial vectors are available for expression of human proteins (reviewed in ref. 13) , we have found the pDISPLAY expression system to be of particular utility. The pDISPLAY plasmid has a vector-encoded, C-terminal transmembrane domain and an immunoglobulin kappa (Ig k) chain leader sequence, which targets the protein through the endoplasmic reticulum (ER) and Golgi networks for display on the cell surface 17 . In general, the ER provides efficient quality control and proteins that are secreted tend to be correctly folded [18] [19] [20] . We usually insert a stop codon before the vector-encoded transmembrane anchor to allow soluble protein to be released into the cultured media.
A strong human cytomegalovirus protomer ensures overexpression of the protein of interest, and the presence of a hemagglutinin (HA) tag allows the secreted protein to be selectively purified by immunoaffinity chromatography and detected by western blot.
Adherent HEK293T cells (Fig. 2 ) are easy to maintain, able to express and properly process recombinant human proteins 12, 16 and are highly suitable for use in both average-sized laboratories and highthroughput structural genomic centers. HEK293T cells are widely available and are easily cultured using Dulbecco's modified Eagle's medium (DMEM) supplemented with L-glutamine (1Â GlutaMAX) and 5% (vol/vol) fetal bovine serum (FBS) in a 37 1C incubator with 5% CO 2 . Exhaustive protocols on tissue culture and expression are available [21] [22] [23] [24] [25] . Test expression trials are performed in 6-well (9.5 cm 2 surface area) or in 24-well (1.9 cm 2 surface area) cell culture plates. High-level expression in small volumes is best obtained when the cloned gene of interest is codon-optimized, cells are transfected between 50 and 80% confluency and when a commercial reagent such as FuGENE HD or GeneJuice is used for transfection. The detection and analysis of dilute amounts of protein secreted into conditioned media are performed by western blot or ELISA analysis using antibodies directed to both linear and conformational epitopes. The use of an antibody against a linear epitope allows detection of total protein expressed, regardless of quality, whereas use of an antibody against a conformational epitope (if available) distinguishes properly folded from misfolded proteins. In our experience, although the vast majority of antibodies against conformational epitopes work well in western blots, binding of some antibodies of unusual conformational sensitivity may be disrupted by SDS-PAGE of their cognate antigens. In this case, non-denaturing immunoblots using native gels, ELISAs or dot blots with the target's natural ligand (if available) are alternate methods for the detection of proper folding.
Considerations for cell culture scale-up and purification A variety of containers, such as T225 cm 2 cell culture flasks, roller bottles (850 cm 2 ) or CellSTACKS (636 cm 2 per layer) can be used for HEK293T culture and expression. We favor the 10-layer CellSTACK system for larger-scale expression and 2-or 5-layer CellSTACKS for smaller scale exploratory studies (Fig. 2) . Cell-STACKS provide equivalent or larger surface area for cell attachment and growth than other vessels, yet package cell culture space effectively, thus requiring less incubator space and labor. Although disposable CellSTACKS are more costly than roller bottles, they can be made more cost-effective by washing and recycling the vessel.
Although we often use FuGENE HD in our laboratory for test transfections, the cost of this reagent for use in large-scale expression is prohibitively expensive. We have found that the use of traditional inexpensive transfection reagents, such as calcium phosphate (reagent of choice in our laboratory) or branched PEI 12, 26, 27 , provides excellent transfection efficiencies and cost savings. Transfection is best performed when the cell population is in the late S phase of the cell cycle (exponential growth phase) 28 , and in our hands this corresponds to B70% cell confluency. We have also found that calcium phosphateÀDNA precipitation is efficient when performed on ice for 20 min. Formation and solubility of calcium phosphateÀDNA precipitate are highly sensitive to incubation temperature and timing, therefore any changes in incubation temperature will require a re-optimization of the timing and ratios of calcium, phosphate and DNA 28, 29 .
In our laboratory, glycoproteins are secreted into liter-scale volumes of conditioned media and are efficiently purified via a two-step procedure. First, large volumes of media are rapidly concentrated to more manageable amounts using a Centramate tangential flow filtration system. Then the recombinant protein is captured by affinity chromatography on an anti-HA column with high affinity and capacity. Bound proteins are gently eluted from anti-HA columns by competition with a synthetic HA peptide. Afterwards, the anti-HA affinity matrix can be regenerated multiple Figure 1 | Workflow for the HEK293T-microfluidic crystallization screening platform. Using this system, constructs can be screened for expression and crystallization and scaled up for structural studies in a matter of 4 weeks. times without loss of performance. Alternatively, dilute concentrations of secreted protein may be loaded directly onto the affinity column without prior concentration, although this process is slower, or proteins may be fractionated by ammonium sulfate precipitation and reconstituted before affinity capture. Many other affinity purification tags such as biotin, glutathione S-transferase, myc-epitope, Flag and polyhistidine have also been developed. However, we prefer the HA tags for the ease of antibody-based purification and low cross-reactivity with host cell proteins. In our experience, low-yield proteins purified by metal affinity chromatography retain a number of host cell contaminants and require additional purification steps before crystallization.
Strategies for the removal of N-linked glycans N-linked glycans attached to proteins expressed in mammalian cells are usually complex, chemically and conformationally heterogeneous and frequently detrimental to the formation of well-ordered crystal lattices. Several strategies have been used to overcome the 'glycosylation problem' . Two popular methods involve using either an N-acetylglycosaminyltransferase I (GnT I)-deficient HEK293S cell line 30 or addition of glycan anabolic inhibitors such as swainsonine or kifunensine 16 to cell culture medium. Both strategies yield more homogeneous, high mannose-type oligosaccharide chains, which can be removed by EndoH deglycosylation 16 . We favor an alternate approach that involves production of native glycoproteins without inhibitors and enzymatic deglycosylation of the resulting protein under native conditions using peptide N-glycosidase F (PNGaseF). Although deglycosylation with PNGaseF has been shown to increase aggregation in some proteins 31 , not all PNGaseF-treated proteins aggregate, and PNGaseF is the most efficient glycosidase available. PNGaseF also has the broadest substrate specificities and cleaves between the asparagine side chain and the innermost N-acetylglucosamine (GlcNAc), thus removing the entire glycan moiety. Occasionally, some glycan attachment sites are buried or masked by the local protein structure and PNGaseF is unable to gain access. In such an event, the use of the EndoF series of glycosidases may be beneficial. The EndoF glycosidases have a unique glycan substrate preference (Fig. 3 ) and tend to be less sensitive to protein conformation, due to their cleavage between the two GlcNAc oligosaccharides in the chitobiose core, and may trim glycans for which PNGaseF treatment was unsuccessful. In some cases, sequential or simultaneous removal of terminal sugars from complex oligosaccharides may need to be removed using neuraminidase, b-galactosidase and N-acetylglucosaminidase before subsequent deglycosylation with EndoF or PNGaseF.
Considerations for crystallization
The use of robotic liquid handling systems has considerably reduced time and protein quantity required for crystallization screening. Indeed, presently available robots can accurately dispense B100 nl of protein or reagent per drop. A recent, additional improvement in protein crystallization is the development of microfluidic circuits to dispense even smaller volumes of protein and reagents for crystallization. We recommend the use of the Fluidigm Topaz microfluidic free interface diffusion system, as outlined in the protocol below. The Topaz microfluidic screening chips (Fig. 4) contain interconnected miniaturized channels and elastomeric rubber valves that control the interface of protein sample and precipitant. Initially, diffusion of protein and precipitant sets a concentration gradient to allow the sampling of a wide However, EndoF2 prefers biantennary complex-type oligosaccharides and to a lesser extent, oligomannose sugars, while EndoF3 cleaves both biantennary and triantennary glycans. Tetra-antennary oligosaccharides are not cleaved by the EndoF series of enzymes and require sequential hydrolysis down to a Man 3 GlcNAc 2 structure. Neuraminidase is an exoglycosidase that removes terminal sialic acid residues from hybrid, biantennary, triantennary and tetra-antennary oligosaccharides. It is sometimes necessary to remove these negatively charged saccharides prior to deglycosylation with EndoH, EndoF or PNGaseF. area of crystallization space. Subsequently, vapor permeability of the reaction chamber allows dehydration to further concentrate the sample, yielding results within 7 days. Quality hits can then be translated into standard 0.5-2.0 ml size hanging drop, vapor diffusion experiments. The system is quite expensive but, in our hands, has been a key determinant in the feasibility of structural analyses of some difficult targets. The Topaz system allows the screening of 96 different crystallization conditions with a mere 1.5 ml of protein, whereas standard laboratory liquid handling robotics will require almost seven times more protein.
This makes the Topaz system highly beneficial for crystallization screening of targets that are difficult to express or obtain. An increasing number of mammalian protein structures, including those of glycosylated proteins, have indeed been determined from initial crystallization hits obtained from microfluidic-based diffusion [32] [33] [34] [35] [36] [37] [38] [39] . . Sodium azide, NaN 3 (Sigma, cat. no. S8032) ! CAUTION Sodium azide is highly toxic by inhalation, ingestion or skin absorption. It should not be allowed to come into contact with heavy metals or their salts because it may react to form heavy metal azides, which are shock-sensitive explosives. Containers of sodium azide should be stored in secondary containers in a cool, dry secured storage separated from acids. Excess sodium azide and waste material containing this substance should be properly disposed in accordance with institutional, city, state and federal guidelines.
MATERIALS
. Glycine Western blot analysis TIMING 8 h 7| Decant the supernatant and microcentrifuge at 16,000g for 20 min at RT. To detect expression, mix 10 ml aliquots of cell culture supernatant with 3Â SDS-PAGE non-reducing sample buffer and separate at 200 V for 45 min on a 10-15% SDS-Tris-HCl polyacrylamide gel or another suitable polyacrylamide gel. m CRITICAL STEP Do not denature sample by heating or adding reducing agent, as this will interfere with recognition by antibodies directed to conformational epitopes, preventing analysis of proper protein fold.
8| Activate the Immobilon-P membrane by soaking it for 2 min in 100% methanol followed by a 2 min soak in 1Â transfer buffer.
9| Assemble western blot transfer apparatus, fill reservoir with 1Â transfer buffer and transfer at 100 V for 1 h. Immerse apparatus in ice to avoid overheating. 20| Pipette this solution dropwise onto 67 ml of pre-chilled 2Â HBS on ice. Vortex or mix well. 2Â HBS should be made freshly or stored frozen to prevent pH drift.
21|
Incubate on ice for 20 min. Solution should become cloudy from formation of a fine white precipitate. m CRITICAL STEP Timing of the calcium phosphate-DNA mixture on ice is critical; do not exceed or drop below 20 min incubation.
22| Add calcium phosphate-DNA mixture to the media in the 10-layer CellSTACK. For optimal transfection, cells should be at B70% confluency. Thoroughly mix with media, distribute evenly over cells and incubate in CO 2 incubator (5% CO 2 3. Block remaining protein-binding sites in microtiter plate wells for 1 h using 100 ml of 1Â PBS-BSA. 4 . Remove the blocking solution and rinse with 1Â PBS-Tween-20. 5. Add 50 ml of the media containing the secreted protein and incubate overnight at 4 1C. For quantitative results, always compare signal of unknown sample to those from a standard curve and perform experiments in triplicate. 6. Remove the media and wash the plate five times with 1Â PBS-Tween-20. 7. Add 50 ml of a mouse anti-HA antibody (1:1,000 dilution in 1Â PBS-BSA) and incubate for 1 h at room temperature. 8. Wash the plate five times with 1Â PBS-Tween-20. 9. Add 50 ml of a goat anti-mouse IgG horseradish-peroxidase-conjugated secondary antibody (1:2,500 dilution in 1Â PBS-BSA) and incubate for 1 h at room temperature. 10. Wash each well 10 times with 1Â PBS-Tween-20. 11. Add 50 ml of 3,3¢,5,5¢-tetramethylbenzidine (TMB) substrate solution from the Pierce TMB substrate kit to each well and incubate for 15-30 min at room temperature or until desired color develops. ! CAUTION TMB should be kept out of direct light, as it is photosensitive and should also be handled as a mutagen. 12. Add 50 ml of 2 M H 2 SO 4 to stop the reaction. 13. Read the optical density at 450 nm.
Supernatant harvest and concentration TIMING 4 h 23| Harvest supernatant 4 days post-transfection. Centrifuge the supernatant at 10,000g for 20 min at RT and filter using a 0.22 mm vacuum filter apparatus. Note that the 10-layer CellSTACKS can be re-used, as described in EQUIPMENT SETUP.
24| Concentrate the supernatant to 150 ml using the Centramate tangential flow filtration system. Buffer-exchange the concentrated sample into PBS by adding 500 ml of 1Â PBS and concentrating down to 150 ml, repeating this process five times. Recirculate the sample through the system for 30 min to recover additional sample from the membrane.
Purification TIMING 1 d
25| Pre-equilibrate a 1 ml anti-HA affinity column with 1Â PBS and load sample by gravity at a flow rate of o1 ml min À1 .
26| Wash the column with 10 ml of 1Â PBS (Optional step: Use 1Â PBS-Tween-20 to remove BSA contaminants).
27| Wash the column with 30 ml of 1Â PBS.
28| Dissolve the synthetic HA peptide in 1Â PBS (1 mg ml À1 ) and pre-warm to 37 1C. ? TROUBLESHOOTING 36| Analyze the deglycosylation reaction by Coomassie-stained SDS-PAGE, anti-HA-probed immunoblot analysis or mass spectrometry. Deglycosylation should result in a molecular weight size shift of bands visualized by western blot (see the ANTICIPATED RESULTS). To identify whether the glycoprotein is completely deglycosylated, compare the molecular weight of the deglycosylated glycoprotein (obtained by mass spectrometry) to its theoretical protein-only molecular weight. Note that some deglycosylation reactions may not lead to complete removal of oligosaccharides, as glycan sites may be sterically hindered from enzyme access.
37| Select deglycosylation enzyme and reaction condition yielding the most homogeneous sample. Small-scale test reaction volumes and starting material are scaled up linearly for preparative use.
38| Separate deglycosylated glycoprotein from enzyme and cleaved glycans using size-exclusion chromatography prior to crystallization.
Microfluidic crystallization screening TIMING setup: 3 h; crystal growth: 7 d 39| Concentrate purified protein to 10-20 mg ml À1 using an Amicon Ultra-0.5 microcentrifugal concentrator. It may be helpful to determine ideal protein concentration for crystallization using the PCT kit from Hampton Research or another commercial vendor. In general, initial concentration of protein needs to be higher for free interface diffusion experiments than that typically used for vapor diffusion experiments, due to the direct mixing of both precipitant and protein in the reaction chambers.
40| Pipette 750 ml appropriately diluted Hydration Fluid Concentrate onto each PVA strip inside the hydration chamber and close the chamber lid. For most screens, a 2:1 ratio of Hydration Fluid Concentrate to water is sufficient, whereas for other screens, such as OptiMix-3 (a high salt screen), a 1:1 dilution is better.
41| Run the Prep script on the Topaz IFC Controller to activate control valves and charge the hydrated chip.
42| Using an eight-channel micropipettor, add 15 ml of crystallization sparse matrix screen (OptiMix-1,2,3, PEG or other commercial/in-house screens) into the appropriate precipitant well. m CRITICAL STEP Perform this within 20 h of Steps 40-42 to avoid dehydration of the crystallization reagent in the precipitant well. Examine the chip under a light microscope to ensure the absence of bubbles at the bottom of reagent wells, which would interfere with proper dispensing of reagent into the microfluidic circuitry.
43| Pipette 1.5 ml of protein into the protein inlet (marked on the chip with blue square(s)).
44| Run the load script. Check under a light microscope that all chambers are filled. ? TROUBLESHOOTING 45| Record a time ¼ 0 image scan (negative control) using the AutoInspeX II workstation.
46| Initiate diffusion using the FID Control RT script.
47| Store screening chip in a vibration-free incubator and monitor for crystal hits and growth over a 7-day period using the AutoInspeX II. ? TROUBLESHOOTING 48| Score the crystallization results (we use a class I-IV scale, Fig. 5 ). Select best crystallization hits (class I or II) for translation to traditional, 0.5-to 2.0-ml-size hanging drop vapor diffusion. Class III or IV crystals may require additional screening in Fluidigm 1.96 screening chips to improve crystal quality. Chances of successful translation increase when crystals of high quality (class I or II) are chosen. See manufacturer's translation guide for more detailed instructions.
? TROUBLESHOOTING ? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 . Note that the times indicated are estimates, and some steps may require additional time. For example, we utilize a general two-step purification composed of anti-HA and size-exclusion chromatography. However, some proteins will require additional purification steps to achieve homogeneity. In addition, enzymatic deglycosylation may lead to increased protein sample heterogeneity due to incomplete deglycosylation. This may require additional optimization of the glycosidase reaction conditions or screening of glycan site mutations. Note that the scale up of HEK293T cells for the CellSTACK preparation (prior to large-scale transient transfection) may be performed in parallel with the small-scale expression and western blot analysis steps.
ANTICIPATED RESULTS
Crystal structures of viral glycoproteins are difficult to achieve given the challenges to production, purification, crystallization and diffraction inherent in the heavily glycosylated, oligomeric, metastable and flexible nature of these proteins. The expression and crystallization platform described here was instrumental in the determination of the structure of the trimeric, prefusion Z. ebolavirus glycoprotein (ZEBOV GP) 15 . In the case of ZEBOV GP, the strategy described here allowed rapid expression screening for over 140 constructs containing various truncations and multiple combinations of mutations to N-X-S/T glycosylation sequons. Moreover, the HEK293T cell culture of the best constructs could be subsequently scaled up to quantities that allowed growth and screening of 50,000 crystals. It is anticipated that this platform will be a useful tool not just for viral glycoproteins but also for mammalian proteins in general. Constructs selected for scale-up should be characterized by a single strong band at the proper molecular weight on both linear anti-HA and conformation-dependent antibody immunoblots, indicating adequate expression level, monodispersity and proper folding (Fig. 6a, for example) . In our laboratory, large-scale expression in HEK293T cells routinely results in the production of B2-10 mg of protein per liter of media. It is expected that glycans produced in HEK293T cells can be efficiently removed by PNGaseF (Fig. 6b) . However, deglycosylation is often incomplete due to poor steric access of the attachment site by the local conformation of the protein. In the case of ZEBOV GP, resistant glycan sites were removed by site-directed mutagenesis of the N-X-S/T glycosylation sequons 15 .
Microfluidic free interface diffusion crystallization (Topaz) uses only 6-7 ml of protein (10 mg ml À1 ) to screen 384 sparse matrix conditions and yields results within 7 days. Protein crystals usually appear closer to the right-hand side of the chamber, which is the region of highest protein concentration. However, the concentration gradient formed in the horizontal axis of the chamber may sometimes permit crystallization in the middle of the chamber. Crystals closest to or contained within the precipitant inlet side (far left) are usually salt. Crystallization hits can be scored into four classes (I-IV; Fig. 5 ). Class I crystals appear perfect, with sharp edges and thickness in three dimensions. Class II crystals are similar to class I, but have minor defects, such as irregular, jagged or rounded edges or satellites. Class III crystals are small needle or crystalline clusters, whereas class IV crystals are showers of microcrystals or spherulites. In the case of ZEBOV GP and other projects in our group, the success (a) Small-scale expression screening of selected Zaire ebolavirus GP truncation variants. Conditioned media containing EBOV GP variants was harvested 4 days post-transfection, and 10 ml of each culture supernatant was separated on a non-denaturing 10-15% gradient SDS-Tris-HCl polyacrylamide gel and probed with mAb-anti-HA or mAb-KZ52 (conformational). The KZ52 antibody 42 was isolated from a human survivor of a 1995 outbreak in Kikwit, Democratic Republic of the Congo (formerly Zaire) and recognizes an epitope bridging both the attachment and fusion subunits of Zaire ebolavirus GP 15 . All ZEBOV GP variants were overexpressed and secreted, as illustrated by the anti-HA probed immunoblot. However, only wild-type GP and GP trunc-A were recognized by KZ52, suggesting that this particular truncation has not significantly altered the native fold. (b) PNGaseF deglycosylation of HEK293T-expressed ZEBOV GP trunc-A. The extent of deglycosylation was monitored by both non-denaturing western blot using KZ52 as the primary antibody and non-reducing, Coomassie-stained SDS-PAGE analysis. As a positive control for complete deglycosylation, ZEBOV GP trunc-A was denatured at 95 1C for 5 min with 0.5% (wt/vol) SDS and treated with PNGaseF. Note that a significant fraction of denatured ZEBOV GP trunc-A is not recognized by the conformational antibody, KZ52, but a molecular weight size shift between the native and denatured deglycosylation reactions suggest incomplete deglycosylation at two N-linked sites. Analysis of the crystal structure confirms that local protein structure at these sites would limit enzyme access. of translation is highly dependent on the quality of the crystal hit and number of unique hits obtained. Class I and II crystal hits have high translation percentages and can often be translated directly into similar conditions of the crystallization screen. Translation of class III and IV crystals tends to be difficult and likely requires additional optimization of pH, salts, PEG or additives using a 1.96 chip to yield more crystalline class I-and II-type crystals prior to translation. 
